Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:post-hocanalysis from the phase III, double-blind, placebo- and active-comparator-controlled VOYAGE 1/2 trials
- Authors
- Youn, Sang Woong; Yu, Dae Young; Kim, Tae Yoon; Kim, Byung Soo; Lee, Seung Chul; Lee, Jeung Hoon; Choe, Yong-Beom; Lee, Joo-Heung; Choi, Jee-Ho; Roh, Joo Young; Jo, Seong Jin; Lee, Eun-So; Shin, Min Kyung; Lee, Min-Geol; Jiang, Jingzhi; Lee, YoungJa
- Issue Date
- Jan-2022
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- interleukin-23; Psoriasis; VOYAGE 1; VOYAGE 2
- Citation
- Journal of Dermatological Treatment, v.33, no.1, pp.535 - 541
- Journal Title
- Journal of Dermatological Treatment
- Volume
- 33
- Number
- 1
- Start Page
- 535
- End Page
- 541
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80936
- DOI
- 10.1080/09546634.2020.1770174
- ISSN
- 0954-6634
- Abstract
- Background: The phase 3 studies, VOYAGE 1 and 2, were conducted to assess guselkumab in the treatment of patients with moderate-to-severe psoriasis. Objectives: To investigate the efficacy and safety of guselkumab in Korean patients. Methods: The Korean sub-population of VOYAGE 1 and 2 study patients were included in this analysis. Efficacy and safety were evaluated through Weeks 24 and 28, respectively. Results: Of 126 randomized Korean patients, 30, 63, and 33 received placebo, guselkumab, and adalimumab, respectively. At Week 16, guselkumab was superior to placebo in achieving an Investigator’s Global Assessment (IGA) score of 0 or 1 (cleared or minimal; 90.5 vs. 20.0%, p<.001) and a Psoriasis Area and Severity Index (PASI) 90 response (71.4 vs. 3.3%, p<.001). At week 24, a significantly higher proportion of guselkumab-treated patients achieved PASI 75 and IGA 0 (clear skin) responses compared to adalimumab-treated patients (PASI 75: 93.7 vs. 66.7%, p<.001; IGA 0: 52.4 vs. 21.2%, p=.004). Through Week 28, guselkumab and adalimumab showed comparable safety profiles. Conclusion: The efficacy and safety of guselkumab in Korean psoriasis patients through 28 weeks were consistent with findings for the overall VOYAGE 1 and 2 study population. © 2020, © 2020 Taylor & Francis Group, LLC.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80936)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.